Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Importance of the Unstirred Water Layer and Hepatocyte Membrane Integrity In Vitro for Quantification of Intrinsic Metabolic Clearance.

Wood FL, Houston JB, Hallifax D.

Drug Metab Dispos. 2018 Mar;46(3):268-278. doi: 10.1124/dmd.117.078949. Epub 2017 Dec 12.


Clearance Prediction Methodology Needs Fundamental Improvement: Trends Common to Rat and Human Hepatocytes/Microsomes and Implications for Experimental Methodology.

Wood FL, Houston JB, Hallifax D.

Drug Metab Dispos. 2017 Nov;45(11):1178-1188. doi: 10.1124/dmd.117.077040. Epub 2017 Sep 8. Erratum in: Drug Metab Dispos. 2017 Dec;45(12 ):1239.


Characterization of the comparative drug binding to intra- (liver fatty acid binding protein) and extra- (human serum albumin) cellular proteins.

Rowland A, Hallifax D, Nussio MR, Shapter JG, Mackenzie PI, Brian Houston J, Knights KM, Miners JO.

Xenobiotica. 2015;45(10):847-57. doi: 10.3109/00498254.2015.1021403. Epub 2015 Mar 24.


Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG.

Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. Review.


Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.

Hallifax D, Houston JB.

J Pharm Sci. 2012 Aug;101(8):2645-52. doi: 10.1002/jps.23202. Epub 2012 Jun 14.


Clearance-dependent underprediction of in vivo intrinsic clearance from human hepatocytes: comparison with permeabilities from artificial membrane (PAMPA) assay, in silico and caco-2 assay, for 65 drugs.

Hallifax D, Turlizzi E, Zanelli U, Houston JB.

Eur J Pharm Sci. 2012 Apr 11;45(5):570-4. doi: 10.1016/j.ejps.2011.12.010. Epub 2011 Dec 24.


Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.

Zanelli U, Caradonna NP, Hallifax D, Turlizzi E, Houston JB.

Drug Metab Dispos. 2012 Jan;40(1):104-10. doi: 10.1124/dmd.111.042309. Epub 2011 Oct 13.


Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Hallifax D, Foster JA, Houston JB.

Pharm Res. 2010 Oct;27(10):2150-61. doi: 10.1007/s11095-010-0218-3. Epub 2010 Jul 27.


Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo.

Donato MT, Hallifax D, Picazo L, Castell JV, Houston JB, Gomez-Lechón MJ, Lahoz A.

Drug Metab Dispos. 2010 Sep;38(9):1449-55. doi: 10.1124/dmd.110.033605. Epub 2010 May 25.


Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines.

Hallifax D, Galetin A, Houston JB.

Xenobiotica. 2008 Apr;38(4):353-67. doi: 10.1080/00498250701834665 .


Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.

Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG.

Drug Metab Rev. 2007;39(1):159-234. Review.


Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement.

Hallifax D, Houston JB.

Drug Metab Dispos. 2006 Apr;34(4):724-6; author reply 727. No abstract available. Erratum in: Drug Metab Dispos. 2006 Jun;34(6):1078.


Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB.

Xenobiotica. 2005 Jun;35(6):603-25.


Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines.

Hallifax D, Rawden HC, Hakooz N, Houston JB.

Drug Metab Dispos. 2005 Dec;33(12):1852-8. Epub 2005 Sep 20.


CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions.

Galetin A, Ito K, Hallifax D, Houston JB.

J Pharmacol Exp Ther. 2005 Jul;314(1):180-90. Epub 2005 Mar 22.


Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.

Galetin A, Brown C, Hallifax D, Ito K, Houston JB.

Drug Metab Dispos. 2004 Dec;32(12):1411-20. Epub 2004 Sep 1.


Supplemental Content

Loading ...
Support Center